Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response

摘要: // Yingqiang Zhang 1 , Wenzhe Fan Kangshun Zhu 2 Ligong Lu 3 Sirui Fu Jinhua Huang 4 Yu Wang Jianyong Yang 5 Yonghui Yao Jiaping Li Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China Radiology, Third Guangdong General Medical Imaging and University Cancer Center & State Key Laboratory Oncology in Southern China, Correspondence to: Li, e-mail: lijiaping3s@126.com Keywords: hepatocellular carcinoma, transarterial chemoembolization, radiofrequency ablation, complete response, sorafenib Received: March 04, 2015      Accepted: May 21, Published: June 03, 2015 ABSTRACT Aims: To assess the efficacy continued administration for patients with unresectable carcinoma (HCC) treated local regional therapy (LRT) after a response (CR), also, adverse events discontinuation were observed. Methods: Between April 2008 2012, 956 consecutive HCC LRT (transarterial ablation) combined retrospectively investigated. Of these, 157 CR enrolled: 102 them to receive (test group) other 55 stopped receiving (control group). Results: median recurrence-free survival (RFS), post-complete overall (pOS) (OS) test control groups 11 months (95% CI: 6.1, 15.9), 25 20.7, 29.3) 33 29.2, 36.8) 12 10.4, 13.6), 28 CI 24.2, 31.8) 34 30.8, 37.2) respectively. differences RFS, pOS OS between not significant ( P = 0.768, 0.797 0.730, respectively). related resolved quality life (QoL) scores improved. Conclusions: Patients who achieved did benefit from terms or OS. reversible, may improve QoL have CR.